<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196505</url>
  </required_header>
  <id_info>
    <org_study_id>2017061</org_study_id>
    <nct_id>NCT03196505</nct_id>
  </id_info>
  <brief_title>The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery</brief_title>
  <acronym>Exparel</acronym>
  <official_title>The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is prospective, randomized trial in which the efficacy of liposomal bupivacaine
      (ExparelÂ®) is compared to standard bupivacaine local surgical site injection in reducing
      total IV and oral morphine equivalents required after laparoscopic bariatric surgery.
      Liposomal bupivacaine is a 72-hour bupivacaine that is slowly released from tissue over the
      course of three days. Having a long acting local anesthetic should provide better pain
      control than conventional bupivacaine which has a 3.5-hour half-life. In some studies, the
      use of liposomal bupivacaine has been shown to decrease pain and narcotic use after surgery.
      This has not yet been studied in bariatric patients and the use of liposomal bupivacaine can
      potentially improve patient post-operative pain control, decrease narcotic use, decrease
      hospital length of stay and readmission rates and improve patient satisfaction after
      bariatric surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine equivalents</measure>
    <time_frame>within 1 week post-operatively</time_frame>
    <description>in hospital total oral and IV morphine equivalents required after laparoscopic bariatric surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Pain Score</measure>
    <time_frame>within 48 hours post operatively.</time_frame>
    <description>Average pain scores by blinded nurse obtained</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel 266 MG Per 20 ML Injection</intervention_name>
    <description>Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>EXPAREL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing elective laparoscopic sleeve gastrectomy or Roux-en-Y gastric
             bypass surgeries.

          -  Fulfills NIH criteria for bariatric surgery

        Exclusion Criteria:

          -  Patients deemed not a candidate for laparoscopic bariatric surgery

          -  Patients with previous bariatric or gastric surgeries.

          -  BMI &lt;35 and &gt; 60 kg/m2

          -  Preoperative inability to ambulate and confined to wheelchair.

          -  American Society of Anesthesiologist (ASA) score &gt;3

          -  Concurrent ventral hernia repair or intraoperative extensive lysis of adhesions

          -  Not able to understand informed consent, or unwilling to sign consent.

          -  Not able to understand and read English

          -  Currently pregnant or lactating.

          -  Age &lt;18 or &gt;65

          -  Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.

          -  Patients requiring opiate use within 30 days prior to time of surgery.

          -  Patients with reported use of narcotics greater than 2 weeks in preceding year before
             surgery.

          -  Patients with history of substance abuse, alcohol addiction

          -  Patients with diagnosis of chronic pain, history of fibromyalgia, chronic regional
             pain syndrome (dystrophic pain syndrome).

          -  Bupivacaine use within 96 hours before operation

          -  Prisoners

          -  Bariatric surgery operation &gt;3 hours.

          -  More than 5 laparoscopic incision sites used during surgery, conversion to open
             operation, placement of a feeding tube or drain.

          -  Patients with renal failure or hepatic failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pearl Ma, MD</last_name>
    <phone>5592614500</phone>
    <email>pma@fresno.ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fresno Heart and Surgical Hospital</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pearl Ma, MD</last_name>
      <phone>559-261-4500</phone>
      <email>pma@fresno.ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aaron Lloyd, MPH</last_name>
      <phone>5594338000</phone>
      <email>ALloyd@communitymedical.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kelvin Higa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pearl Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Pearl Ma</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Anesthetics, Local</keyword>
  <keyword>Liposomal Bupivacaine</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Postoperative Complications</keyword>
  <keyword>Roux-en-Y Gastric Bypass</keyword>
  <keyword>Sleeve Gastrectomy</keyword>
  <keyword>Laparoscopic Bariatric Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Narcotics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

